enGene, Inc., a clinical-stage biotechnology company, announced on Thursday that it has named Richard Bryce, MBChB, MRCGP, MFPM as its new chief medical officer, effective 19 September 2023.

In the new role, Dr Bryce will handle the clinical development of EG-70, the company's lead product candidate for non-muscle invasive bladder cancer (NMIBC), and the development strategy for the company's therapeutic range of tissue-targeted non-viral gene therapies.

Dr Bryce has served as chief medical officer at Rain Oncology, chief medical & scientific officer at Puma Biotechnology and senior director of Clinical Science for Onyx Pharmaceuticals.